LAKE CHARLES, La., Jan. 13, 2022 /PRNewswire/ -- Wavegate Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care. "We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain," said Erich Wolf, MD, PhD, Chief Executive Officer. "We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art." StimuLux™ is a component of Wavegate Corporation's Ellipse neuromodulation platform which integrates multiple patented technologies which aim to systematically address unmet clinical needs within the neuromodulation industry. CAUTION: StimuLux™ optical reflectometry is limited by Federal Law to investigational use only.

April 23, 2020- Lake Charles, LA. Wavegate Technologies, LLC, has been restructured as a Delaware C-corporation. This gives Wavegate Corporation additional flexibility in stock offerings to investors and provides a widely-accepted legal framework under Delaware law.

May 1, 2020- Lake Charles, LA. Wavegate Corporation completed its Series A investment round on Friday, May 1, 2020. It is with deep appreciation that we wish to thank our investors who came through during these financially tumultuous times associated with the COVID-19 pandemic. Thank you for sharing our vision for StimuLux technology and supporting Wavegate Corporation's mission to provide transformative pain relief as we continue our quest to improve the human condition.

Wavegate is pleased to announce that John Tattory has assumed the role of interim CFO. After several years in the CFO role at Wavegate, Mr. Robert Ehlers is changing roles to an advisor at Wavegate to allow him to concentrate on his core business. We thank Robert for his service and look forward to John's tenure in this strategic role. More about John: John Tattory currently serves as a Senior Consultant at LifeSci Associates, a firm specializing in interim C-suite consultants for the life science industry. Mr. Tattory has over 25 years of financial leadership experience primarily in the biotechnology and life sciences sectors. He has broad-based, public and private company financial leadership experience directing U.S. and international financial operations, executing strategic transactions, raising capital through equity and debt financings, and managing investor relations. Prior to joining LifeSci Associates, John served as Chief Financial Officer at Cerapedics Inc., a privately held, ortho-biologics company focused on developing and commercializing its proprietary technology platform to enhance the science of bone repair and Windtree Therapeutics, a publicly-traded, biotechnology company focused on the development of novel therapeutics intended to address acute cardiovascular and pulmonary diseases. Mr. Tattory has raised over $400 million in capital through public and private equity offerings, structured debt facilities and licensing agreements. He previously held financial management positions at Bristol-Myers Squibb and Ernst & Young LLP. John is a certified public accountant (currently inactive status) and holds a B.S. in Commerce degree from Rider University.

Wavegate is pleased to announce that Matt F. Thomas has joined Wavegate's Board of Directors. Matt brings deep domain experience to Wavegate, having served as the General Manager for Medtronic's Spinal Cord Stimulation business. Matt is a welcome addition to the senior management team at Wavegate and rounds out the executive experience required to navigate Wavegate's Ellipse platform to the best-in-class market leader. Matt Thomas has over 25 years of experience leading medical device businesses. He has broad experience in strategy, business development, marketing, sales & new product development. Prior to joining Cerapedics in 2020, Matt was Vice President & General Manager for Medtronic’s Spinal Cord Stimulation & Early Interventions pain business. Previously, Matt also led a turnaround of Medtronic’s Kyphon business, returning it to growth for the first time since the acquisition. He joined Medtronic in 2002 and also had leadership roles in spine, diabetes, and deep brain stimulation. Prior to Medtronic, he was a product manager with Sonic Innovations and founder of HyperX, a health care data services company. He has an MBA from Carnegie Mellon University, a BS in economics from the University of Utah and studied at Johns Hopkins University.